TRUEX PAUL F 4
4 · Milestone Pharmaceuticals Inc. · Filed Jun 1, 2022
Insider Transaction Report
Form 4
TRUEX PAUL F
Director
Transactions
- Exercise/Conversion
Common Shares
2022-05-31$1.12/sh+8,016$8,978→ 8,016 total - Exercise/Conversion
Stock Option (right to buy)
2022-05-31−822→ 117 totalExercise: $2.66Exp: 2028-11-20→ Common Shares (822 underlying) - Exercise/Conversion
Common Shares
2022-05-31$2.66/sh+822$2,187→ 76,780 total - Exercise/Conversion
Stock Option (right to buy)
2022-05-31−8,016→ 0 totalExercise: $1.12Exp: 2025-08-26→ Common Shares (8,016 underlying) - Exercise/Conversion
Stock Option (right to buy)
2022-05-31−22,870→ 2,659 totalExercise: $1.54Exp: 2028-10-15→ Common Shares (22,870 underlying) - Exercise/Conversion
Common Shares
2022-05-31$1.54/sh+45,072$69,411→ 53,088 total - Exercise/Conversion
Common Shares
2022-05-31$1.54/sh+22,870$35,220→ 75,958 total - Purchase
Common Shares
2022-05-31$5.60/sh+5,000$28,000→ 81,780 total - Exercise/Conversion
Stock Option (right to buy)
2022-05-31−45,072→ 0 totalExercise: $1.54Exp: 2027-07-21→ Common Shares (45,072 underlying)
Footnotes (3)
- [F1]Fully vested and exercisable.
- [F2]Twenty-five percent (25%) of the shares subject to the option shall vest on October 15, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
- [F3]Twenty-five percent (25%) of the shares subject to the option shall vest on November 21, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.